<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457897</url>
  </required_header>
  <id_info>
    <org_study_id>150119</org_study_id>
    <secondary_id>15-DK-0119</secondary_id>
    <nct_id>NCT02457897</nct_id>
  </id_info>
  <brief_title>Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations</brief_title>
  <official_title>Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in Patients With Insulin Receptor Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Insulin receptor mutation causes high blood sugars and sometimes diabetes complications.
      Researchers want to see if thyroid hormone helps.

      Objectives:

      - To see if thyroid hormone treatment changes how the body handles sugar in people with
      insulin receptor mutation and improves blood sugar in people with diabetes.

      Eligibility:

      - People ages 12 65 with an insulin receptor mutation.

      Design:

        -  Study part 1:19-day clinic stay. Participants will be monitored for 4 days. Then for 15
           days they will take a thyroid hormone pill 3 times a day. Participants will have:

        -  Blood tests.

        -  Heart rate and skin temperature monitored.

        -  All their food provided.

        -  Two 5-hour sessions in a special room. They will wear special clothes and sometimes sit
           still.

        -  Two small tubes inserted in veins. One will deliver tiny amounts of sugar and fat with a
           non-radioactive tracer. Participants will also drink water with a tracer. The other tube
           will collect blood.

        -  A sweet drink. Participants may have finger stick blood sugar tests.

        -  Glucose-monitoring device inserted into body fat for two 24-hour periods.

        -  Adults may have samples of fat and muscle taken.

        -  Heart ultrasound.

        -  PET-CT scan in a machine. An intravenous catheter will be placed in an arm vein. A small
           amount of radioactive substance will be injected.

        -  DEXA scan of body fat and bone density.

        -  Participants with poorly controlled diabetes will then take thyroid hormone at home for
           6 months. They will have blood drawn and sent to the study team monthly.

        -  After about 3 months, they will have an overnight visit. After 6 months, they will have
           a 4-day visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Patients with mutations of the insulin receptor have extreme insulin resistance. This
      frequently results in diabetes in childhood that is extremely difficult to manage with
      conventional diabetes therapies, including insulin at doses 10-50 fold higher than usual.
      Poorly controlled diabetes, in turn, leads to microvascular complications (e.g. blindness)
      and early death. Hyperthyroidism, whether endogenous (e.g. Graves' disease) or exogenous,
      increases energy expenditure, activates brown adipose tissue, and enhances skeletal muscle
      perfusion, leading to enhanced glucose disposal. In a single patient with mutation of the
      insulin receptor and poorly controlled diabetes despite maximal therapy, iatrogenic mild
      hyperthyroidism for treatment of thyroid cancer resulted in normalization of glycemic
      control, suggesting that thyroid hormone treatment could have therapeutic benefit in this
      rare disease.

      Aim

      The purpose of this study is to determine if treatment with thyroid hormone will increase
      glucose disposal in patients with mutations of the insulin receptor, and thereby improve
      glycemic control. The hypotheses to be tested are:

        1. Thyroid hormone will increase whole-body glucose disposal in patients with insulin
           receptor mutations.

        2. This increased glucose disposal will be mediated via increased glucose uptake in brow
           adipose tissue (BAT) and muscle.

        3. Increases in glucose disposal will result in improved glycemic control.

      Methods

      This study is a non-randomized pre-post design, conducted in two sequential parts. Part 1 is
      a short-term (2 week) proof-of-principle study to test whether thyroid hormone will increase
      glucose disposal in patients with insulin receptor mutations (with or without diabetes), and
      the mechanisms by which increased glucose disposal occurs. Part 2 is a longer term (6 month)
      therapeutic study to test whether thyroid hormone will result in improved glycemic control in
      diabetic patients with insulin receptor mutations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 17, 2015</start_date>
  <completion_date type="Actual">September 18, 2018</completion_date>
  <primary_completion_date type="Actual">September 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Body Glucose Disposal in the Fasting State</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Glucose Uptake</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Glucose Uptake</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Abnormal Glucose Metabolism</condition>
  <arm_group>
    <arm_group_label>Patients with insulin receptor mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>Oral supplement given every 8 hours</description>
    <arm_group_label>Patients with insulin receptor mutation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  2 WEEKS STUDY:

        INCLUSION CRITERIA:

        1. Mutation of the insulin receptor (either recessive or dominant negative). If mutation
        status is not known prior to enrollment, subjects will undergo genotyping at enrollment. In
        the unanticipated event that a patient does not have a mutation of the insulin receptor, he
        or she will not complete the study and his or her data will not be included in the
        analysis.

        EXCLUSION CRITERIA:

          1. Changes in doses of diabetes medications (including metformin, insulin, sulfonylureas,
             thiazolidinediones, leptin, GLP-1 agonists, DPP4 inhibitors, etc.) in the preceding 10
             weeks.

          2. Any medical condition or medication that will increase risk to the subject (e.g.
             ischemic or structural heart disease, congestive heart failure, uncontrolled
             hypertension, or arrhythmia) or that will interfere with interpretation of study data.

          3. Disorders that would lead to erratic gastrointestinal absorption or loss of thyroid
             hormone from the gut (severe diarrhea, celiac disease, use of bile acid sequestrants,
             excessive consumption of soybean products).

          4. Any form of endogenous hyperthyroidism or hypothyroidism at baseline.

          5. Current or recent (past 8 weeks) use of thyroid hormone or anti-thyroid drugs.

          6. Extreme disorders of thyroid hormone binding to thyroid binding globulin (excess or
             deficiency) or protein loss (nephrotic range proteinuria) that would lead to
             difficulties achieving a consistent thyroid hormone level for study.

          7. Known presence of a rare clinical disorder that leads to thyroid hormone insensitivity
             (known T3 receptor mutations, selenocysteine insertion sequence-binding protein 2
             (SBP2) abnormalities, monocarboxylate transporter defects).

          8. Current use of beta blockers

          9. Pregnancy or breast feeding

         10. Any EKG abnormality that could increase risk of T3 treatment (resting sinus
             tachycardia (age adjusted norms), atrial fibrillation, myocardial ischemia, left or
             right ventricular excitation block, left ventricular hypertrophy or extrasystoles)

         11. Known allergy or hypersensitivity to any form of thyroid hormone

         12. Known adrenal insufficiency

         13. Dependence on oral anticoagulant medications (adults only)

         14. Use of tricyclic anti-depressants, as transient cardiac arrhythmias have been observed
             with the concomitant use of thyroid hormone.

         15. Use of cholestyramine.

         16. History of clinically significant osteoporosis per investigator judgment (e.g.
             previous fragility fracture)

        6 MONTHS STUDY:

        Patients must meet all inclusion and exclusion criteria for the short-term study, plus have
        poorly controlled diabetes, defined as a hemoglobin A1c greater than or equal to 7%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca J Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2015-DK-0119.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976 Apr 1;294(14):739-45.</citation>
    <PMID>176581</PMID>
  </reference>
  <reference>
    <citation>Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R, Hugendubler L, Cochran C, Solomon J, Chen C, Gorden P. Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insulin resistance. J Clin Endocrinol Metab. 2010 Jan;95(1):256-62. doi: 10.1210/jc.2009-0543. Epub 2009 Nov 6.</citation>
    <PMID>19897683</PMID>
  </reference>
  <reference>
    <citation>Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004 Jul;83(4):209-22. Review.</citation>
    <PMID>15232309</PMID>
  </reference>
  <verification_date>September 18, 2018</verification_date>
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <results_first_submitted>October 7, 2019</results_first_submitted>
  <results_first_submitted_qc>November 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2019</results_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brown Adipose Tissue</keyword>
  <keyword>Liothyronine</keyword>
  <keyword>Insulin Receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02457897/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With Insulin Receptor Mutation</title>
          <description>Liothyronine: Oral supplement given every 8 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 Short-term (2 Weeks) Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 Long-term (6 Month) Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">Two patients were not eligible for Part 2 study because their HbA1c was less than 7.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Insulin Receptor Mutation</title>
          <description>Liothyronine: Oral supplement given every 8 hours</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.84" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Body Glucose Disposal in the Fasting State</title>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Insulin Receptor Mutation</title>
            <description>Liothyronine: Oral supplement given every 8 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Glucose Disposal in the Fasting State</title>
          <units>μmol/kg LBM (Lean Body Mass)/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.47" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1C</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Insulin Receptor Mutation</title>
            <description>Liothyronine: Oral supplement given every 8 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1C</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Glucose Uptake</title>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Insulin Receptor Mutation</title>
            <description>Liothyronine: Oral supplement given every 8 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Glucose Uptake</title>
          <units>μmol/min/100ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Glucose Uptake</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Insulin Receptor Mutation</title>
            <description>Liothyronine: Oral supplement given every 8 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Glucose Uptake</title>
          <units>μmol/min/100ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients With Insulin Receptor Mutation</title>
          <description>Liothyronine: Oral supplement given every 8 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction (after eating Indian food)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rebecca Brown</name_or_title>
      <organization>NIDDK</organization>
      <phone>301-594-0609</phone>
      <email>Rebecca.Brown@NIH.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

